Trial Profile

Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risankizumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms VALUE
Sponsors AbbVie

Most Recent Events

18 Jun 2024 Planned End Date changed from 30 Aug 2025 to 30 Jul 2025.
18 Jun 2024 Planned primary completion date changed from 30 Aug 2025 to 30 Jul 2025.
12 Mar 2024 Results (n=181) assessing improvements in patient reported outcome (PRO) parameters corresponding to absolute Psoriasis Area and Severity Index (aPASI) for the German cohort presented at the American Academy of Dermatology annual Meeting 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com